Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects

References

• Patsalos PN, St Louis EK. The epilepsy prescriber’s guide to antiepileptic drugs. 3rd ed. Cambridge: Cambridge University Press; 2018.
   Google Scholar
• Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526–548.
   Google Scholar
• Johannessen Landmark C, Johannessen SI, Tomson T. Host factors affecting antiepileptic drug delivery – pharmacokinetic variability. Adv Drug Deliv Rev. 2012a;64:896–910.
   Google Scholar
• Johannessen Landmark C, Johannessen SI, Tomson T. Dosing strategies of antiepileptic drugs – from one dose to individualisation of treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016;18(4):367–383.
   Google Scholar
• Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347–363.
   Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49:1239–1276.
   Google Scholar
• Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia. 2017;58(7):1234–1243.
   Google Scholar
• Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35:4–29.
   Google Scholar
• Baftiu A, Feet SA, Larsson PG, et al. Utilization of antiepileptic drugs in the elderly vs younger patients with epilepsy and psychiatric comorbidity. Epilepsy Res. 2018;139:35–42.
   Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319.
   Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
   Google Scholar
• Nunes VD, Sawyer L, Neilson J, et al. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;26:e344:281.
   Google Scholar
• Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother. 2007;7:179–193.
   Google Scholar
• Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;8:627–645.
   Google Scholar
• Verotti A, Iapadre G, Di Donato G, et al. Pharmacokinetic considerations for anti-epileptic drugs in children. Exp Opin Drug Metab Toxicol. 2019;15(3):199–211.
   Google Scholar
• Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405–414.
   Google Scholar
• Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord. 2016;9(2):118–129.
   Google Scholar
• Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007a;46:209–219.
   Google Scholar
• Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005;65:185–188.
   Google Scholar
• Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70:2130–2136.
   Google Scholar
• Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia. 2007b;48:1111–1116.
   Google Scholar
• Mazzucchelli I, Onat FY, Özkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia. 2006;47(3):504–509.
   Google Scholar
• Öhman I, Vitols S, Luef G, et al. Topiramate kinetics during delivery, in the neonatal period, and lactation: preliminary observations. Epilepsia. 2002;43:1157–1160.
   Google Scholar
• Westin AA, Nakken KO, Johannessen SI, et al. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia. 2009;50:480–485.
   Google Scholar
• Reimers A, Helde G, Becser Andersen N, et al. Zonisamide serum concentrations during pregnancy. Epilepsy Res. 2018a;144:25–29.
   Google Scholar
• Öhman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia. 2005;46:1621–1624.
   Google Scholar
• Gerard EE, Meador KJ. An update on maternal use of antiepileptic medications in pregnancy and neurodevelopment outcomes. J Pediatr Genet. 2015;4(2):94–110.
   Google Scholar
• EMA. Visited March 28th, 2019. https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances.
   Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538.
   Google Scholar
• Johannessen Landmark C, Burns ML, Baftiu A, et al. Pharmacokinetic variability of valproate in women of childbearing. Epilepsia. 2017;58(10):e142–e146.
   Google Scholar
• Johannessen Landmark C, Farmen AH, Burns ML, et al. Pharmacokinetic variability of valproate during pregnancy – implications for the use of therapeutic drug monitoring. Epilepsy Res. 2018;141:31–37.
   Google Scholar
• Johannessen SI, Johannessen Landmark C. Antiepileptic drug interactions – basic principles and clinical implications. Curr Neuropharm. 2010;8:254–267.
   Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10:119–140.
   Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)-part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013a;52:927–966.
   Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)-part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013b;52:1045–1061.
   Google Scholar
• Patsalos PN. Antiepileptic drug interactions: a clinical guide. 3rd ed. Switzerland: Springer; 2016.
   Google Scholar
• Hole K, Wollmann BM, Nguyen C, et al. Comparison of CYP3A4-inducing capacity of enzyme-inducing antiepileptic drugs using 4β-hydroxycholesterol as biomarker. Ther Drug Monit. 2018;40(4):463–468.
   Google Scholar
• Bertilsson L, Höjer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27:83–88.
   Google Scholar
• Kudriakova TB, Sirota LA, Rozova GI, et al. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol. 1992;33:611–615.
   Google Scholar
• Johannessen Landmark C, Baftiu A, Tysse I, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine and topiramate-a comparison of the impact of age and comedication. Ther Drug Monit. 2012b;34(4):440–445.
   Google Scholar
• Koristkova B, Grundmann M, Brozmanova H, et al. Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients. Basic Clin Pharmacol Toxicol. 2019;125(1):26–33.
   Google Scholar
• De Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35(1):30–47.
   Google Scholar
• Burns ML, Baftiu A, Opdal MS, et al. Therapeutic drug monitoring of clobazam and its metabolite-Impact of age and comedication on pharmacokinetic variability. Ther Drug Monit. 2016;38(3):350–357.
   Google Scholar
• Karouni M, Henning O, Larsson PG, et al. Psychiatric comorbidity in patients with refractory epilepsy. Epi Behav. 2013;29:77–81.
   Google Scholar
• Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86.
   Google Scholar
• Asconapé JJ. Pharmacokinetic considerations with the use of antiepileptic drugs in patients with HIV and organ transplants. Curr Neurol Neurosci Rep. 2018;18:89.
   Google Scholar
• Sabers A, Öhman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570–571.
   Google Scholar
• Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46:1414–1417.
   Google Scholar
• Galgani A, Palleria C, Iannone LF, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067.
   Google Scholar
• Löscher W, Klotz U, Zimprich F, et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009;50(1):1–23.
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
   Google Scholar
• Bozina N, Sporis IS, Bozina T, et al. Pharmacogenomics and the treatment of epilepsy: what do we know?. Pharmacogenomics. 2019;20(15):1093–1101.
   Google Scholar
• Smith RL, Haslemo T, Refsum H, et al. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid – a large-scale study based on naturalistic therapeutic drug monitoring data. Eur J Clin Pharmacol. 2016;72(9):1099–1104.
   Google Scholar
• Smith RL, Haslemo T, Chan HF, et al. Clinically relevant effect of UGT1A4*3 on lamotrigine serum concentration is restricted to postmenopausal women – a study matching therapeutic drug monitoring and genotype data from 534 patients. Ther Drug Monit. 2018;40(5):567–571.
   Google Scholar
• Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301. eCollection 2017.
   Google Scholar
• Mirza N, Vaseiva O, Appleton R. An integrative in silico system for predicting dysregulated genes in the human epileptic focus: application to SLC transporters. Epilepsia. 2016;57:1467–1474.
   Google Scholar
• Franco V, Baruffi K, Fransesca Crema TM, et al. Determination of perampanel in dried blood spots; applicability to therapeutic drug monitoring. Ther Drug Monit. 2019 Jul 29. Epub ahead of print.
   Google Scholar
• Velghe S, Deprez S, Stove CP. Fully automated therapeutic drug monitoring of antiepileptic drugs making use of dried blood spots. J Chromatogr A. 2019;1601:95–103.
   Google Scholar
• Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53(11):961–973.
   Google Scholar
• Shah NM, Hawwa AF, Millership JS, et al. Adherence to antiepileptic medicines in children: a multiple-methods assessment involving dried blood spot sampling. Epilepsia. 2013;54:1020–1027.
   Google Scholar
• Linder C, Neideman M, Wide K, et al. Dried blood spot self-sampling by guardians of children with epilepsy is feasible; comparison with plasma for multiple antiepileptic drugs. Ther Drug Monit. 2019;41(4):509–518.
   Google Scholar
• Linder C, Wide K, Walander M, et al. Comparison between dried blood spot and plasma sampling for therapeutic drug monitoring of antiepileptic drugs in children with epilepsy: a step towards home sampling. Clin Biochem. 2017;50(7–8):418–424.
   Google Scholar
• D’Urso A, Cangemi G, Barco S, et al. LC-MS/MS-based quantification of 9 antiepileptic drugs from a dried sample spot device. Ther Drug Monit. 2019;41(3):331–339.
   Google Scholar
• D’Urso A, Rudge J, Patsalos PN, et al. Volumetric absorptive microsampling: a new sampling tool. Ther Drug Monit. 2019;41(5):681–692.
   Google Scholar
• Johannessen SI, Gerna M, Bakke J, et al. CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Br J Clin Pharmacol. 1976;3:575–582.
   Google Scholar
• Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An Update Clin Pharmacokinet. 1986;11:177–198.
   Google Scholar
• Pisani F, Caputo M, Fazio A, et al. Interaction of carbamazepine-10-11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia. 1990;31:339–342.
   Google Scholar
• Burianová I, Borecka K. Routine therapeutic monitoring of the active metabolite of carbamazepine: is it really necessary? Clin Biochem. 2015;48:866–869.
   Google Scholar
• Stockis A, Sargentini-Maier ML, Brodie MJ. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. Epilepsy Res. 2016;128:163–168.
   Google Scholar
• Reimers A, Andsnes Berg J, Larsen Burns M, et al. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther. 2018b;12:271–280.
   Google Scholar
• Specht U, Elsner H, May TW, et al. Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav. 2003;4(5):487–495.
   Google Scholar
• Samsonsen C, Reimers A, Bråthen G, et al. Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study. Epilepsia. 2014;55(11):e125–128.
   Google Scholar
• Touw DJ, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27:10–17.
   Google Scholar
• Eadie MJ. Plasma antiepileptic drug monitoring in a neurological practice: a 25-year experience. Ther Drug Monit. 1994;16:458–468.
   Google Scholar
• Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet. 1995;29:29–35.
   Google Scholar
• Rane CT, Dalvi SS, Gogtay NJ, et al. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001;52:193–195.
   Google Scholar
• Salih MR, Bahari MB, Shafie AA, et al. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children with structural-metabolic epilepsy. Epilepsy Res. 2013;104:151–157.
   Google Scholar
• Hussain SA, Ortendahl JD, Bentley TGK, et al. The economical burden of caregiving in epilepsy: an estimate based on a survey of US caregivers. Epilepsia. 2020 Jan 17. Epub ahead of print.
   Google Scholar
• Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191–204.
   Google Scholar
• Woo E, Chan YM, Yu YL, et al. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia. 1988;29:129–139.
   Google Scholar
• Buchthal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol. 1960;2:624–630.
   Google Scholar
• Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology. 1984;34:1252–1255.
   Google Scholar
• Schmidt D, Einicke I, Haenel FT. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol. 1986;43:263–265.
   Google Scholar
• Gidal BE, Ferry J, Majid O, et al. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490–1497.
   Google Scholar
• Svendsen T, Brodtkorb E, Reimers A, et al. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate – a national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. Epilepsy Res. 2017a;129:125–131.
   Google Scholar
• Svendsen T, Brodtkorb E, Baftiu A, et al. Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability. Neurochem Res. 2017b;42(7):2077–2083.
   Google Scholar
• Steinhoff BJ, Hübers E, Kurth C, et al. Plasma concentration and clinical effects of perampanel – the Kork experience. Seizure. 2019;28:18–22.
   Google Scholar
• Burns ML, Nikanorova M, Baftiu A, et al. Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway. Ther Drug Monit. 2019a;41(3):340–347.
   Google Scholar
• Contin M, Albani F, Riva R, et al. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013;35(6):849–852.
   Google Scholar
• May TW, Helmer R, Bien CG, et al. Influence of dose and antiepileptic comedication on lacosamide serum concentrations in patients with epilepsy of different ages. Ther Drug Monit. 2018;40(5):620–627.
   Google Scholar
• Johannessen Landmark C, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions. Epilepsy Res. 2009;87:31–39.
   Google Scholar
• Baftiu A, Johannessen Landmark C, Rudberg Rusten I, et al. Safety aspects of utilization of antiepileptic drugs in epilepsy vs. non-epilepsy disorders. Eur J Clin Pharmacol. 2016;72(10):1245–1254.
   Google Scholar
• Burns ML, Kinge E, Stokke Opdahl M, et al. Therapeutic drug monitoring of gabapentin in various indications. Acta Neurol Scand. 2019b;130(5):446–454.
   Google Scholar
• Conway JM, Collins JF, Macias FM, et al. Factors in variability of serial gabapentin concentrations in elderly patients with epilepsy. Pharmacotherapy. 2017;37(10):1197–1203.
   Google Scholar
• Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM “nouveau”. Ther Drug Monit. 2004;26:145–151.
   Google Scholar
• World Health Organization. Adherence to long term therapies – evidence for action. World Health Organization 2003. Available from: http://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf
   Google Scholar
• Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49:446–454.
   Google Scholar
• Henning O, Johannessen Landmark C, Nakken KO, et al. Nonadherence to treatment regimens in epilepsy from the patients’ perspective and predisposing factors: differences between intentional and non-intentional lack of adherence. Epilepsia. 2019a;60(5):e58–e62.
   Google Scholar
• Johannessen Landmark C, Fløgstad I, Syvertsen M, et al. Treatment with AEDs and challenges for patients with JME. Epi Behav. 2019;98:110–116.
   Google Scholar
• Henning O, Lossius MI, Lima MH, et al. Refractory epilepsy and nonadherence to drug treatment. Epilepsia Open. 2019b;4:618–623.
   Google Scholar
• Carpentier N, Jonas J, Frismand S, et al. Direct evidence of nonadherence to antiepileptic medication in refractory focal epilepsy. Epilepsia. 2013;54(1):e20–e23.
   Google Scholar
• Lunardi M, Lin K, Walz R, et al. Single antiepileptic drug levels do not predict adherence and nonadherence. Acta Neurol Scand. 2019;139(2):199–203.
   Google Scholar
• Johannessen Landmark C, Fløgstad I, Baftiu A, et al. Long term therapeutic drug monitoring of AEDs in patients with JME. Epilepsy Res. 2019;155:106148.
   Google Scholar
• Mevaag M, Henning O, Baftiu A, et al. Discrepancies between physicians’ prescriptions and patients’ use of antiepileptic drugs. Acta Neurol Scand. 2017;135:80–87.
   Google Scholar
• Holtkamp M, Theodore WH. Generic antiepileptic drugs – safe or harmful in patients with epilepsy? Epilepsia. 2018;59(7):1273–1281.
   Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069–1077.
   Google Scholar
• Hao X, Goldberg D, Kelly K, et al. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013;29(1):4–6.
   Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XiV) II. Drugs in more advanced clinical development. Epilepsia. 2018;59(10):1842–1866.
   Google Scholar
• Tomson T, Dahl M, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev. 2007c;1:CD002216.
   Google Scholar
• Fröscher W, Eichelbaum M, Gugler R, et al. A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol. 1981;224:193–201.
   Google Scholar
• Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia. 2000;41:222–230.
   Google Scholar
• Thangaratinam S, Marlin N, Newton S, et al. AntiEpileptic drug monitoring in PREgnancy (EMPiRE): a double-blind randomized trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018;22(23):1–152.
   Google Scholar
• Chen Z, Liew D, Kwan P. Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PLoS One. 2014;9(5):e96990.
   Google Scholar
• Tassaneeyakul W, Prabmeechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics. 2016;26(5):225–234.
   Google Scholar
• Chouchi M, Kaabachi W, Tizaoui K, et al. The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: an updated systematic review and meta-analysis. Rev Neurol (Paris). 2018;174(5):278–291.
   Google Scholar